Dr Edmond Ma and his team develop the world’s first metal compound as the inhibitor of the enzyme KDM5A for treating triple-negative breast cancer, one of the most difficult forms of breast cancer to treat.


馬迪龍博士與團隊發現全球首個能抑制人體內「去甲基化酶KDM5A」的金屬化合物類抑制劑,有望治療乳癌中最難治療的三陰性乳癌。

The diagram shows the use of the new inhibitor for the treatment of triple-negative breast cancer.


銠化合物類抑制劑在三陰性乳癌細胞和動物模型中抑制去甲基化酶KDM5A的工作示意圖。

Date: 29 Aug 2018 (Wednesday)

Archive

HKBU scholars in world-first breakthrough for difficult-to-treat breast cancer

浸大首創金屬類抑制劑 有望用於治療乳癌中最難治療的三陰性乳癌

Chemists at HKBU have discovered the use of a metal compound that inhibits the enzyme closely associated with triple-negative breast cancer (TNBC), one of the most difficult forms of breast cancer to treat. The metal compound is found to inhibit the TNBC tumours with less toxicity in mice, thus their work has further unmasked the role of the enzyme, lysine-specific demythylase 5A (KDM5A), in TNBC. The reported compound shows tremendous potential for the development of drugs for TNBC therapy. The results of this study were published in the leading chemistry journal Angewandte Chemie International Edition.

The team was led by Dr Edmond Ma Dik-lung, Associate Professor of the Department of Chemistry. The team developed the compound using a metal named rhodium as a direct, potent and selective inhibitor of KDM5A, in other words the compound can effectively target KDM5A which is a key limitation of existing KDM5A inhibitors. To find out more, please visit: https://cpro.hkbu.edu.hk/en/press_release/detail/81/

浸大化學系副教授馬迪龍博士率領團隊,發現全球首個金屬化合物,能有效抑制人體內一種酶「去甲基化酶KDM5A」,可用於治療乳癌中最難治療的一類──三陰性乳癌。團隊發現該金屬化合物有效抑制小鼠身體內三陰性乳癌細胞的生長,且毒副作用明顯較低,因此,上述發現進一步揭示KDM5A對三陰性乳癌的影響,有望開發出新一代抗癌藥物。研究成果近期在國際頂尖的化學期刊《德國應用化學》發表。

團隊發現金屬「銠」化合物類抑制劑,可以直接在KDM5A上發揮作用,高效並能針對性地抑制KDM5A的活性。更多詳情請瀏覽﹕https://cpro.hkbu.edu.hk/zh-hant/press_release/detail/81/